Symbols / IMTX Stock $10.79 -5.27% Immatics N.V.

Healthcare • Biotechnology • Germany • NCM
IMTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Harpreet Singh Ph.D.
Exch · Country NCM · Germany
Market Cap 1.47B
Enterprise Value 1.07B
Income -196.45M
Sales 48.27M
FCF (ttm) -128.19M
Book/sh 4.26
Cash/sh 3.50
Employees 589
Insider 10d —
IPO Dec 12, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E -6.07
PEG —
P/S 30.55
P/B 2.53
P/C —
EV/EBITDA -6.21
EV/Sales 22.25
Quick Ratio 11.07
Current Ratio 11.72
Debt/Eq 3.23
LT Debt/Eq —
EPS (ttm) -2.01
EPS next Y -1.78
EPS Growth —
Revenue Growth -64.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-12
ROA -18.08%
ROE -37.10%
ROIC —
Gross Margin -280.87%
Oper. Margin -196.76%
Profit Margin 0.00%
Shs Outstand 136.67M
Shs Float 67.27M
Insider Own 17.92%
Instit Own 75.78%
Short Float 5.62%
Short Ratio 16.80
Short Interest 5.16M
52W High 12.41
vs 52W High -13.05%
52W Low 4.48
vs 52W Low 140.96%
Beta 1.31
Impl. Vol. 25.00%
Rel Volume 2.88
Avg Volume 478.90K
Volume 1.38M
Target (mean) $18.75
Tgt Median $18.00
Tgt Low $11.00
Tgt High $25.00
# Analysts 8
Recom Strong_buy
Prev Close $11.39
Price $10.79
Change -5.27%
About

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$18.75
Mean price target
2. Current target
$10.79
Latest analyst target
3. DCF / Fair value
$-16.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.79
Low
$11.00
High
$25.00
Mean
$18.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-28 init TD Cowen — → Buy —
2025-11-24 main Chardan Capital Buy → Buy $25
2025-11-19 main Mizuho Outperform → Outperform $23
2025-11-18 main Guggenheim Buy → Buy $19
2025-09-18 init Guggenheim — → Buy $16
2025-05-28 init Deutsche Bank — → Buy $10
2025-04-01 reit Cantor Fitzgerald Overweight → Overweight —
2024-11-19 main B of A Securities Buy → Buy $15
2024-10-07 init Piper Sandler — → Overweight $19
2024-09-09 reit Cantor Fitzgerald — → Overweight —
2024-09-05 reit Cantor Fitzgerald — → Overweight —
2024-05-16 main Mizuho Buy → Buy $16
2023-11-02 init Cantor Fitzgerald — → Overweight —
2023-03-31 init Mizuho — → Buy $12
2023-03-23 main Chardan Capital — → Buy $25
2022-08-10 main Chardan Capital — → Buy $28
2022-06-03 main SVB Leerink — → Outperform $26
2022-03-24 main SVB Leerink — → Outperform $25
2021-07-15 main SVB Leerink — → Outperform $27
2021-03-17 main SVB Leerink — → Outperform $26
News
RSS: Latest IMTX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
48.27
-69.03%
155.84
+188.60%
54.00
-68.76%
172.83
Operating Revenue
48.27
-69.03%
155.84
+188.60%
54.00
-68.76%
172.83
Operating Expense
230.28
+18.43%
194.45
+24.87%
155.72
+8.99%
142.88
Research And Development
183.83
+24.14%
148.08
+24.79%
118.66
+11.13%
106.78
Selling General And Administration
51.18
+10.19%
46.45
+21.60%
38.20
+5.74%
36.12
General And Administrative Expense
51.18
+10.19%
46.45
+21.60%
38.20
+5.74%
36.12
Salaries And Wages
26.29
+11.93%
23.48
+7.83%
21.78
+4.10%
20.92
Other Gand A
24.90
+8.42%
22.96
-39.88%
38.20
+5.74%
36.12
Other Operating Expenses
-4.73
-5969.23%
-0.08
+93.15%
-1.14
-4280.77%
-0.03
Total Expenses
230.28
+18.43%
194.45
+24.87%
155.72
+8.99%
142.88
Operating Income
-182.02
-371.36%
-38.62
+62.04%
-101.72
-439.60%
29.95
Total Operating Income As Reported
-182.02
-371.36%
-38.62
+62.04%
-101.72
-439.60%
29.95
EBITDA
-185.09
-637.16%
34.46
+138.75%
-88.93
-277.71%
50.04
Normalized EBITDA
-152.44
-10874.59%
-1.39
+98.28%
-80.65
-304.70%
39.40
Reconciled Depreciation
12.40
+1.43%
12.22
+68.99%
7.23
+3.83%
6.97
EBIT
-197.49
-988.31%
22.23
+123.12%
-96.16
-323.25%
43.07
Total Unusual Items
-32.65
-191.09%
35.85
+532.77%
-8.28
-177.82%
10.64
Total Unusual Items Excluding Goodwill
-32.65
-191.09%
35.85
+532.77%
-8.28
-177.82%
10.64
Special Income Charges
—
—
—
0.00
Restructuring And Mergern Acquisition
—
—
—
0.00
Net Income
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Pretax Income
-198.44
-1029.62%
21.35
+122.01%
-96.99
-330.74%
42.04
Net Non Operating Interest Income Expense
16.23
-32.69%
24.11
+85.30%
13.01
+805.01%
1.44
Interest Expense Non Operating
0.95
+6.77%
0.89
+6.62%
0.83
-19.94%
1.04
Net Interest Income
16.23
-32.69%
24.11
+85.30%
13.01
+805.01%
1.44
Interest Expense
0.95
+6.77%
0.89
+6.62%
0.83
-19.94%
1.04
Interest Income Non Operating
17.18
-31.29%
25.00
+80.58%
13.85
+459.17%
2.48
Interest Income
17.18
-31.29%
25.00
+80.58%
13.85
+459.17%
2.48
Other Income Expense
-32.65
-191.09%
35.85
+532.77%
-8.28
-177.82%
10.64
Gain On Sale Of Security
-32.65
-191.09%
35.85
+532.77%
-8.28
-177.82%
10.64
Tax Provision
-1.99
-132.46%
6.13
+361.32%
-2.35
-116.36%
14.33
Tax Rate For Calcs
0.00
-96.51%
0.00
+1087.41%
0.00
-92.91%
0.00
Tax Effect Of Unusual Items
-0.33
-103.18%
10.29
+5238.75%
-0.20
-105.52%
3.63
Net Income Including Noncontrolling Interests
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Net Income From Continuing Operation Net Minority Interest
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Net Income From Continuing And Discontinued Operation
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Net Income Continuous Operations
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Minority Interests
—
—
—
0.00
Normalized Income
-164.12
-1487.65%
-10.34
+88.06%
-86.57
-518.43%
20.69
Net Income Common Stockholders
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Diluted EPS
—
0.14
+111.86%
-1.18
-314.55%
0.55
Basic EPS
—
0.14
+111.86%
-1.18
-310.71%
0.56
Basic Average Shares
—
105.74
+31.28%
80.55
+20.24%
66.99
Diluted Average Shares
—
106.80
+32.59%
80.55
+18.09%
68.21
Diluted NI Availto Com Stockholders
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
562.34
-19.22%
696.15
+36.51%
509.96
+25.05%
407.82
Current Assets
504.01
-19.94%
629.55
+40.10%
449.37
+19.15%
377.15
Cash Cash Equivalents And Short Term Investments
469.34
-22.35%
604.45
+41.93%
425.89
+17.58%
362.20
Cash And Cash Equivalents
345.92
+46.11%
236.75
+8.37%
218.47
+47.10%
148.52
Other Short Term Investments
123.42
-66.44%
367.70
+77.27%
207.42
-2.93%
213.69
Receivables
6.88
+2.02%
6.75
+17.57%
5.74
+416.38%
1.11
Accounts Receivable
6.10
+4.13%
5.86
+43.10%
4.09
+268.41%
1.11
Other Receivables
—
—
—
—
Taxes Receivable
0.78
-11.94%
0.89
-45.99%
1.64
+59.46%
1.03
Prepaid Assets
12.92
+7.24%
12.05
+13.46%
10.62
+1.62%
10.45
Hedging Assets Current
—
—
—
—
Other Current Assets
14.87
+135.66%
6.31
-11.36%
7.12
-48.55%
13.84
Total Non Current Assets
58.33
-12.41%
66.59
+9.90%
60.59
+97.60%
30.67
Net PPE
54.90
-13.84%
63.71
+11.67%
57.05
+115.39%
26.49
Gross PPE
84.66
-11.61%
95.78
+19.84%
79.92
+70.15%
46.97
Accumulated Depreciation
-29.76
+7.17%
-32.06
-40.23%
-22.86
-11.63%
-20.48
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
12.59
-4.30%
13.15
+2.37%
12.85
+3.55%
12.41
Machinery Furniture Equipment
8.90
-30.08%
12.73
+15.18%
11.05
+44.07%
7.67
Other Properties
34.41
-10.57%
38.48
+25.71%
30.61
-13.69%
35.47
Leases
28.76
-8.44%
31.42
+23.63%
25.41
+562.49%
3.84
Goodwill And Other Intangible Assets
1.58
-2.89%
1.63
+6.96%
1.52
-6.68%
1.63
Other Intangible Assets
1.58
-2.89%
1.63
+6.96%
1.52
-6.68%
1.63
Non Current Prepaid Assets
1.08
+224.62%
0.33
-76.45%
1.41
-25.81%
1.91
Other Non Current Assets
0.77
-16.14%
0.92
+52.07%
0.60
-76.31%
2.54
Total Liabilities Net Minority Interest
78.24
-35.50%
121.30
-58.51%
292.35
+42.98%
204.47
Current Liabilities
43.01
-36.73%
67.99
-56.57%
156.55
+47.06%
106.45
Payables And Accrued Expenses
21.18
-13.41%
24.46
-26.02%
33.06
+153.25%
13.06
Payables
2.69
-80.62%
13.88
-10.58%
15.52
+18.90%
13.06
Accounts Payable
0.34
-96.64%
10.11
+31.91%
7.67
-41.28%
13.06
Current Accrued Expenses
18.49
+74.77%
10.58
-39.68%
17.54
+80.62%
9.71
Pensionand Other Post Retirement Benefit Plans Current
1.71
+8.11%
1.58
+23.65%
1.28
+58.44%
0.81
Total Tax Payable
2.35
-37.65%
3.77
-52.04%
7.86
+1.73%
7.72
Income Tax Payable
0.03
-98.18%
1.76
-59.03%
4.30
+0.00%
4.30
Current Debt And Capital Lease Obligation
2.76
-3.30%
2.85
+9.49%
2.60
+20.61%
2.16
Current Capital Lease Obligation
2.76
-3.30%
2.85
+9.49%
2.60
+20.61%
2.16
Current Deferred Liabilities
15.82
-55.95%
35.91
-64.24%
100.40
+54.57%
64.96
Current Deferred Revenue
15.82
-55.95%
35.91
-64.24%
100.40
+54.57%
64.96
Other Current Liabilities
1.55
-51.36%
3.19
-83.41%
19.21
-26.92%
26.28
Total Non Current Liabilities Net Minority Interest
35.23
-33.93%
53.32
-60.74%
135.79
+38.55%
98.02
Long Term Debt And Capital Lease Obligation
12.88
-3.55%
13.35
+4.33%
12.80
+3.18%
12.40
Long Term Capital Lease Obligation
12.88
-3.55%
13.35
+4.33%
12.80
+3.18%
12.40
Non Current Deferred Liabilities
22.35
-44.08%
39.97
-67.51%
122.99
+43.73%
85.57
Non Current Deferred Revenue
18.54
-45.72%
34.16
-70.43%
115.53
+52.49%
75.76
Non Current Deferred Taxes Liabilities
3.81
-34.41%
5.80
-22.26%
7.47
-23.90%
9.81
Other Non Current Liabilities
—
—
0.00
-90.48%
0.04
Stockholders Equity
484.10
-15.79%
574.84
+164.15%
217.62
+7.01%
203.35
Common Stock Equity
484.10
-15.79%
574.84
+164.15%
217.62
+7.01%
203.35
Capital Stock
1.34
+10.28%
1.22
+43.57%
0.85
+10.43%
0.77
Common Stock
1.34
+10.28%
1.22
+43.57%
0.85
+10.43%
0.77
Share Issued
134.07
+10.30%
121.55
+43.58%
84.66
+10.42%
76.67
Ordinary Shares Number
134.07
+10.30%
121.55
+43.58%
84.66
+10.42%
76.67
Additional Paid In Capital
1,277.34
+9.91%
1,162.14
+41.18%
823.17
+15.26%
714.18
Retained Earnings
-785.99
-33.32%
-589.54
+2.52%
-604.76
-18.55%
-510.11
Gains Losses Not Affecting Retained Earnings
-8.59
-933.37%
1.03
+163.02%
-1.64
-10.47%
-1.48
Other Equity Adjustments
-8.59
-933.37%
1.03
+163.02%
-1.64
-10.47%
-1.48
Total Equity Gross Minority Interest
484.10
-15.79%
574.84
+164.15%
217.62
+7.01%
203.35
Total Capitalization
484.10
-15.79%
574.84
+164.15%
217.62
+7.01%
203.35
Working Capital
461.00
-17.91%
561.57
+91.78%
292.82
+8.17%
270.70
Invested Capital
484.10
-15.79%
574.84
+164.15%
217.62
+7.01%
203.35
Total Debt
15.63
-3.51%
16.20
+5.20%
15.40
+5.77%
14.56
Capital Lease Obligations
15.63
-3.51%
16.20
+5.20%
15.40
+5.77%
14.56
Net Tangible Assets
482.52
-15.82%
573.21
+165.26%
216.09
+7.13%
201.72
Tangible Book Value
482.52
-15.82%
573.21
+165.26%
216.09
+7.13%
201.72
Current Provisions
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-176.63
-11.77%
-158.03
-966.96%
18.23
-81.80%
100.13
Cash Flow From Continuing Operating Activities
-176.63
-11.77%
-158.03
-966.96%
18.23
-81.80%
100.13
Net Income From Continuing Operations
-196.45
-1390.89%
15.22
+116.08%
-94.65
-441.66%
27.70
Depreciation Amortization Depletion
12.40
+1.43%
12.22
+68.99%
7.23
+3.83%
6.97
Depreciation And Amortization
12.40
+1.43%
12.22
+68.99%
7.23
+3.83%
6.97
Other Non Cash Items
-16.23
+32.69%
-24.11
-85.30%
-13.01
-805.01%
-1.44
Stock Based Compensation
15.02
-14.89%
17.64
-14.79%
20.70
-8.26%
22.57
Deferred Tax
-1.99
-132.46%
6.13
+361.32%
-2.35
-116.36%
14.33
Deferred Income Tax
-1.99
-132.46%
6.13
+361.32%
-2.35
-116.36%
14.33
Operating Gains Losses
33.15
+192.17%
-35.97
-509.20%
8.79
+209.98%
-7.99
Gain Loss On Investment Securities
-1.73
+89.98%
-17.26
-930.40%
2.08
+118.99%
-10.95
Net Foreign Currency Exchange Gain Loss
34.13
+282.47%
-18.71
-372.64%
6.86
+132.34%
2.95
Gain Loss On Sale Of PPE
0.75
+74900.00%
0.00
+100.67%
-0.15
0.00
Change In Working Capital
-43.97
+70.84%
-150.78
-278.25%
84.59
+127.04%
37.26
Change In Receivables
-0.24
+86.28%
-1.76
+40.85%
-2.98
-595.10%
-0.43
Changes In Account Receivables
-0.24
+86.28%
-1.76
+40.85%
-2.98
-595.10%
-0.43
Change In Payables And Accrued Expense
—
—
—
—
Change In Payable
—
—
—
—
Change In Account Payable
—
—
—
—
Change In Other Working Capital
-37.62
+74.88%
-149.74
-274.12%
86.00
+88.76%
45.56
Change In Other Current Assets
-6.11
-940.17%
0.73
-53.78%
1.57
+119.98%
-7.87
Investing Cash Flow
204.79
+234.39%
-152.39
-385.49%
-31.39
+85.04%
-209.79
Cash Flow From Continuing Investing Activities
204.79
+234.39%
-152.39
-385.49%
-31.39
+85.04%
-209.79
Net PPE Purchase And Sale
-6.56
+59.69%
-16.27
+46.92%
-30.65
-439.03%
-5.69
Purchase Of PPE
-6.56
+59.70%
-16.27
+47.17%
-30.80
-436.75%
-5.74
Sale Of PPE
0.00
-100.00%
0.00
-98.67%
0.15
+188.46%
0.05
Capital Expenditure
-6.80
+58.71%
-16.48
+46.76%
-30.96
-398.10%
-6.21
Net Investment Purchase And Sale
211.59
+255.69%
-135.91
-23292.25%
-0.58
+99.71%
-203.63
Purchase Of Investment
-338.27
+24.89%
-450.35
-8.43%
-415.32
-91.99%
-216.32
Sale Of Investment
549.86
+74.87%
314.44
-24.18%
414.74
+3166.99%
12.70
Net Intangibles Purchase And Sale
-0.25
-18.75%
-0.21
-31.65%
-0.16
+66.88%
-0.48
Purchase Of Intangibles
-0.25
-18.75%
-0.21
-31.65%
-0.16
+66.88%
-0.48
Financing Cash Flow
97.35
-69.55%
319.68
+278.25%
84.52
-31.68%
123.71
Cash Flow From Continuing Financing Activities
97.35
-69.55%
319.68
+278.25%
84.52
-31.68%
123.71
Net Issuance Payments Of Debt
-2.96
-47.07%
-2.01
+47.73%
-3.85
-35.39%
-2.84
Repayment Of Debt
-2.96
-47.07%
-2.01
+47.73%
-3.85
-35.39%
-2.84
Long Term Debt Payments
-2.96
-47.07%
-2.01
+47.73%
-3.85
-35.39%
-2.84
Net Long Term Debt Issuance
-2.96
-47.07%
-2.01
+47.73%
-3.85
-35.39%
-2.84
Net Common Stock Issuance
107.31
-68.72%
343.01
+279.42%
90.40
-32.78%
134.48
Net Other Financing Charges
-7.00
+67.17%
-21.31
-945.32%
-2.04
+74.29%
-7.93
Changes In Cash
125.51
+1254.42%
9.27
-87.01%
71.36
+407.87%
14.05
Effect Of Exchange Rate Changes
-16.34
-281.42%
9.01
+742.12%
-1.40
-195.12%
1.48
Beginning Cash Position
236.75
+8.37%
218.47
+47.10%
148.52
+11.67%
132.99
End Cash Position
345.92
+46.11%
236.75
+8.37%
218.47
+47.10%
148.52
Free Cash Flow
-183.43
-5.11%
-174.51
-1270.96%
-12.73
-113.55%
93.92
Common Stock Issuance
107.31
-68.72%
343.01
+279.42%
90.40
-32.78%
134.48
Interest Paid CFO
-0.95
-6.77%
-0.89
-205.52%
-0.29
+58.27%
-0.69
Interest Received CFO
26.82
+71.85%
15.61
+53.49%
10.17
+516.56%
1.65
Issuance Of Capital Stock
107.31
-68.72%
343.01
+279.42%
90.40
-32.78%
134.48
Taxes Refund Paid
-4.43
+66.18%
-13.10
-342.50%
-2.96
-1221.43%
-0.22
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category